Coherus Biosciences Inc (NASDAQ:CHRS) price on current trading day, fall -4.79% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $1.39.
A look at the stock’s price movement, the level at last check in today’s session was $1.46, moving within a range at $1.38 and $1.48. The beta value (5-Year monthly) was 0.693. Turning to its 52-week performance, $2.97 and $0.66 were the 52-week high and 52-week low respectively. Overall, CHRS moved -13.66% over the past month.
Coherus Biosciences Inc’s market cap currently stands at around $160.70 million, with investors looking forward to this quarter’s earnings report slated for in February.
Analysts have a consensus estimate of 43.88M for the company’s revenue for the quarter, with a low and high estimate of 36.42M and 58.9M respectively. The average forecast suggests down to a -52.06% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 255.58M, representing a -0.65% decline on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that CHRS is a 50% Buy. On the other hand, the stock is on average a 50% Buy as suggested by medium term indicators while long term indicators are putting the stock in Hold category.
5 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 2 analyst(s) rate the stock as a Hold, 3 recommend CHRS as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
CHRS’s current price about -7.43% and 6.40% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 45.98, while 7-day volatility ratio is 7.53% and 9.67% in the 30-day chart. Further, Coherus Biosciences Inc (CHRS) has a beta value of 0.82, and an average true range (ATR) of 0.14. Analysts have given the company’s stock an average 52-week price target of $6, forecast between a low of $6 and high of $6. Looking at the price targets, the low is -331.65% off recent price level in today’s trading while to achieve the yearly target high, it has to move -331.65%. Nonetheless, investors will most likely welcome a -331.65% jump to $6 which is the analysts’ median price.
If we refocus on Coherus Biosciences Inc (NASDAQ:CHRS), historical trading data shows that trading volumes averaged 1.9 over the past 10 days and 5.01 million over the past 3 months. The company’s latest data on shares outstanding shows there are 115.21 million shares.
The 4.01% of Coherus Biosciences Inc’s shares are in the hands of company insiders while institutional holders own 66.12% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 30.72 million on 2024-12-31, giving us a short ratio of 3.38. The data shows that as of 2024-12-31 short interest in Coherus Biosciences Inc (CHRS) stood at 3111.0 of shares outstanding. Current price change has pushed the stock 0.72% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the CHRS stock continues to rise going into the next quarter.
